DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/4440f0/jordan_pharmaceuti) has announced the addition of the "Jordan Pharmaceuticals and Healthcare Report Q1 2012" report to their offering.
Regionally speaking, Jordan's pharmaceutical market will continue to be viewed as a moderately attractive destination for foreign drugmakers. The country has a well-developed local pharmaceutical industry, which has allowed it to maintain a positive trade balance, and a broadly acceptable intellectual property environment. However, the perceived worsening of its pricing and reimbursement environment will continue to detract investors, especially during the politically unsettled times that have also had a negative impact on the inflows of medical tourists.
Headline Expenditure Projections:
- Pharmaceuticals: JOD412mn (US$581mn) in 2010 to JOD448mn (US$632mn) in 2011; +8.8% in local currency terms and +8.8% in US dollar terms. Forecast down slightly from Q411 due to revised macroeconomic expectations.
- Healthcare: JOD1.60bn (US$2.27bn) in 2010 to JOD1.73bn (US$2.45bn) in 2011; +8.2% in local currency terms and +8.2% in US dollar terms. Forecast down slightly from Q411 due to revised macroeconomic expectations.
- Medical devices: JOD100mn (US$141mn) in 2010 to JOD112mn (US$158mn) in 2011; +11.9% in local currency terms and +11.9% in US dollar terms. Historical figure down significantly from Q411 due to exclusion of re-exports.
Jordan's composite Pharmaceutical and Healthcare Business Environment Ratings score for Q112 is 48.8, a substantial downgrade from 51.3 in the previous quarter. This puts Jordan 10th out of the 30 markets surveyed in the Middle East and Africa (MEA) region. Jordan's rewards and risk scores are relatively evenly balanced, given that we have downgraded Jordan's industry risk rating from 57 out of 100 to 47, as Jordan was named on the Watch List of the Pharmaceutical Research and Manufacturers of America (PhRMA)'s Special 301 submission report for 2011.
Companies Mentioned:
- Pharma International Company
- Arab Pharmaceutical Manufacturers
- Dar al-Dawa
- Hikma Pharmaceuticals
- Jordanian Pharmaceutical Manufacturing Company
- United Pharmaceutical Manufacturers
- Pfizer
- GlaxoSmithKline
- Novartis
- Sanofi
- Merck & Co
For more information visit http://www.researchandmarkets.com/research/4440f0/jordan_pharmaceuti